Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

“The impact of Wegovy on the obesity market has been huge. key opinion leaders (KOLs) interviewed by GlobalData defined it as ‘revolutionary’. Now with Zepbound, the revolution continues ...

Lilly announced the results on Wednesday, claiming that Zepbound outperforms Wegovy, which has been a leader in the weight loss market ... trial that examined the impact of both drugs on patients ...

Analysts are particularly optimistic about the demand for tirzepatide, the active ingredient in Eli Lilly's flagship products Mounjaro and Zepbound ... the market, it could significantly impact ...

The impact of Wegovy on the obesity market has been huge. Key Opinion Leaders (KOLs) interviewed by GlobalData defined it as “revolutionary”. With Zepbound, the revolution continues ...

Researchers compared the safety and efficacy of tirzepatide (brand name Zepbound) and semaglutide ... chiefly that it was not a blinded analysis and participants knew which medication they ...

The analysts expect launches of medicines including Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy to help add $20 billion to the value of the market ... GlobalData’s analysis starts in ...

CVS’s decision directly threatens a sizable portion of Zepbound’s addressable market. The potential impact of CVS's formulary decision regarding Zepbound may be somewhat limited. Lilly ...

People taking Zepbound lost 20.2% of their body weight on average after 72 weeks of treatment in the Lilly-sponsored study, compared with a 13.7% loss for Wegovy patients, Lilly said Wednesday.

According to Bloomberg, the 47% greater weight loss with Zepbound included around two more inches off patients’ waists, a difference researchers told the news outlet can impact blood pressure ...